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Learning objectives
• To evaluate indications for PET-CT in plasma cell dyscrasias and its added value over other imaging modalities with review of literature based evidence and reference to the RCR/RCP guidelines.
• To discuss the use of PET-CT and subsequent clinical impact at our institution with pictorial illustration.
• To discuss the limitations and potential pitfalls of PET-CT with pictorial illustration.
Content organisation
• Role of imaging in the diagnosis, management and follow up of plasma cell dyscrasias.
• Indications for PET-CT and circumstances in which it is and is not likely to be beneficial with review of literature based evidence and RCR/RCP guidelines.
• Use of PET-CT at our institution with subsequent clinical impact in staging of non-secretory disease, myeloma, POEMS disease, assessing plasmacytoma response to treatment and MGUS transformation to myeloma with pictorial illustration.
• Limitations and potential pitfalls of PET-CT with pictorial illustration.
Conclusion
Although PET-CT is recommended by Durie-Salmon Plus, it is not widely adopted. RCR guidelines advise PET-CT for monitoring non secretory myeloma and assessing active disease. At our institution, PET-CT influenced patient management in 95%. PET-CT is useful in staging myeloma, in detection of occult bone/nodal disease and in detecting residual active disease or recurrent disease post chemoradiotherapy/bone marrow transplant. It is of less value in diffuse bone marrow involvement. PET-CT has added value to conventional imaging techniques especially when they are normal, indeterminate or contraindicated. 
